JPS5939423B2 - Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof - Google Patents

Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof

Info

Publication number
JPS5939423B2
JPS5939423B2 JP50023635A JP2363575A JPS5939423B2 JP S5939423 B2 JPS5939423 B2 JP S5939423B2 JP 50023635 A JP50023635 A JP 50023635A JP 2363575 A JP2363575 A JP 2363575A JP S5939423 B2 JPS5939423 B2 JP S5939423B2
Authority
JP
Japan
Prior art keywords
group
general formula
formulas
substituted
tables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP50023635A
Other languages
Japanese (ja)
Other versions
JPS51125263A (en
Inventor
彰祐 岡本
亮二 菊本
嘉邦 玉尾
信二 殿村
和夫 大窪
徹 手塚
明子 土方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Priority to JP50023635A priority Critical patent/JPS5939423B2/en
Priority to NL7512637A priority patent/NL7512637A/en
Priority to GB45339/75A priority patent/GB1516668A/en
Priority to CA239,255A priority patent/CA1073914A/en
Priority to DK498975A priority patent/DK498975A/en
Priority to SE7512530A priority patent/SE431204B/en
Priority to FR7534105A priority patent/FR2290193A1/en
Priority to NO753733A priority patent/NO753733L/no
Priority to DE19752550088 priority patent/DE2550088A1/en
Priority to US05/638,985 priority patent/US4055636A/en
Priority to US05/653,217 priority patent/US4055651A/en
Priority to US05/656,014 priority patent/US4041156A/en
Priority to US05/656,870 priority patent/US4046876A/en
Priority to US05/669,743 priority patent/US4070457A/en
Priority to US05/671,435 priority patent/US4062963A/en
Priority to US05/671,568 priority patent/US4049645A/en
Priority to US05/671,436 priority patent/US4066758A/en
Priority to US05/703,704 priority patent/US4069323A/en
Priority to US05/713,486 priority patent/US4073914A/en
Priority to US05/723,474 priority patent/US4096255A/en
Priority to US05/728,051 priority patent/US4104392A/en
Publication of JPS51125263A publication Critical patent/JPS51125263A/en
Priority to US05/760,668 priority patent/US4073913A/en
Priority to US05/760,745 priority patent/US4066773A/en
Priority to US05/760,929 priority patent/US4101653A/en
Priority to US05/760,587 priority patent/US4072757A/en
Priority to US05/760,677 priority patent/US4069317A/en
Priority to US05/760,586 priority patent/US4066759A/en
Priority to US05/760,740 priority patent/US4069329A/en
Priority to US05/760,738 priority patent/US4073892A/en
Priority to US05/760,667 priority patent/US4073891A/en
Priority to US05/760,744 priority patent/US4072743A/en
Priority to US05/760,654 priority patent/US4108986A/en
Priority to US05/760,719 priority patent/US4073916A/en
Priority to US05/760,673 priority patent/US4125619A/en
Priority to US05/760,585 priority patent/US4072744A/en
Priority to US05/760,727 priority patent/US4069318A/en
Priority to US05/760,672 priority patent/US4093712A/en
Priority to US05/760,676 priority patent/US4097472A/en
Priority to US05/776,195 priority patent/US4097591A/en
Priority to US05/804,334 priority patent/US4125604A/en
Priority to US05/804,331 priority patent/US4140681A/en
Priority to US05/804,368 priority patent/US4131673A/en
Priority to US05/819,872 priority patent/US4133880A/en
Priority to US05/829,483 priority patent/US4139529A/en
Priority to US05/844,196 priority patent/US4154828A/en
Priority to US05/844,188 priority patent/US4117127A/en
Priority to US05/844,181 priority patent/US4168307A/en
Priority to US05/902,855 priority patent/US4173630A/en
Priority to US05/938,711 priority patent/US4201863A/en
Priority to UA2814248A priority patent/UA8371A1/en
Publication of JPS5939423B2 publication Critical patent/JPS5939423B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】 本発明は血液凝固系に関与する重要なたんぱく質分解酵
素の一つであるトロンビンに対し強い阻害作用を有する
N2−ナフタレンスルホニルアルギニンアミド類または
その酸付加塩の製造方法に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for producing N2-naphthalenesulfonylargininamides or acid addition salts thereof, which have a strong inhibitory effect on thrombin, which is one of the important proteolytic enzymes involved in the blood coagulation system. .

N2−ナフタレンスルホニルアルギニンアミドまたはそ
の酸付加塩はトロンビンの阻害剤として強い抗トロンビ
ン作用を示し、医薬上血液凝固を抑制する特異な生理活
生物質であり、抗トロンビン作用が持続的であるという
特徴を有する。
N2-naphthalenesulfonylargininamide or its acid addition salt exhibits a strong antithrombin effect as a thrombin inhibitor, is a unique physiologically active substance that inhibits blood coagulation, and is characterized by a sustained antithrombin effect. has.

本発明はこのように有用なN2−ナフタレンスルホニル
アルギニンアミド類の製法を提供することを目的とする
ものであり、この目的は下記一般式(I)(上記一般式
(I)中でRは一般式(1)−N/R”\R。
The purpose of the present invention is to provide a method for producing N2-naphthalenesulfonylarginine amides that are useful as described above. Formula (1)-N/R”\R.

(式中でR1およびR2は水素原子、アルキル基、シク
ロアルキルアルキル基またはアルコキシ基もしくはアル
コキシカルボニル基で置換されたアルキル基を表わす。
(In the formula, R1 and R2 represent a hydrogen atom, an alkyl group, a cycloalkylalkyl group, or an alkyl group substituted with an alkoxy group or an alkoxycarbonyl group.

)または一般式(2)−NZ(式中ゝ−ノでZはメチレ
ン基−CH2−およびモノ置換メチレン基−C−(R3
はアルキル基、アシル基、アルコキシ基またはアルコキ
シカルボニル基を表わす。
) or the general formula (2) -NZ (in the formula, Z is a methylene group -CH2- and a monosubstituted methylene group -C-(R3
represents an alkyl group, an acyl group, an alkoxy group or an alkoxycarbonyl group.

)から選択される2以上の基ならびにオキシ基−0−、
チオ基−5−、シクロアルキレン基、アルキル置換イミ
ノ基 l(R6はアルキル基0=C=R7 を表わす。
) and an oxy group -0-,
Thio group -5-, cycloalkylene group, alkyl-substituted imino group 1 (R6 represents an alkyl group 0=C=R7.

)、アシル置換イミノ基 1 (R7はアルキル基を表わす。), acyl-substituted imino group 1 (R7 represents an alkyl group.

)およびフェニレン基oから選択される0または1以上
の基が任意の順序に結合した2価基を表わす。
) and a phenylene group o, representing a divalent group in which zero or one or more groups selected from o are bonded in any order.

)で表わされる。)で表わされるアルギニンアミドまた
はその酸付加塩に下記一般式(■)R’−SO2X(■
) (上記一般式(■)中でR’は1−ナフチル基;2−ナ
フチル基;ハロゲン原子、ニトロ基、アルコキシカルボ
ニルオキシ基、ジアルキルアミノ基、シアノ基もしくは
アルキル基で置換された1−ナフチル基または2−ナフ
チル基を表わし、Xはハロゲン原子を表わす。
). ) or its acid addition salt represented by the following general formula (■) R'-SO2X (■
) (In the above general formula (■), R' is a 1-naphthyl group; 2-naphthyl group; 1-naphthyl substituted with a halogen atom, a nitro group, an alkoxycarbonyloxy group, a dialkylamino group, a cyano group, or an alkyl group) group or 2-naphthyl group, and X represents a halogen atom.

ただし、5−(ジメチルアミノ)−1−ナフチル基を除
く。)で表わされるナフタレンスルホニルハロゲニドま
たは置換ナフタレンスルホニルハロゲニドを反応させて
下記一般式(■)(上記一般式(1)中でRは一般式(
1卜N/i:C′1\R9(式中でR1およびR2は水
素原子、アルキル基、シクロアルキルアルキル基または
アルコキシ基もしくはアルコキシカルボニル基で置換さ
れたアルキル基を表わす。
However, 5-(dimethylamino)-1-naphthyl group is excluded. ) or a substituted naphthalenesulfonyl halide represented by the following general formula (■) (in the above general formula (1), R is the general formula (
1 N/i: C'1\R9 (wherein R1 and R2 represent a hydrogen atom, an alkyl group, a cycloalkylalkyl group, or an alkyl group substituted with an alkoxy group or an alkoxycarbonyl group.

)または一般式(2)−】多(式中でZはメチレン基−
CH2− およびモノ置換メチレン基−C−(R3はア
ルキル基、アシル基、アルコキシ基またはアルコキシカ
ルボニル基を表わす。)から選択される2以上の基なら
びにオキシ基−0−、チオ基−S−、シクロアルキレン
基、魯▼υアルキル置換イミノ基 (R6はアルキ
ル基を表わす。
) or the general formula (2)-] poly (in the formula, Z is a methylene group -
two or more groups selected from CH2- and a monosubstituted methylene group -C- (R3 represents an alkyl group, acyl group, alkoxy group or alkoxycarbonyl group), an oxy group -0-, a thio group -S-, Cycloalkylene group, alkyl-substituted imino group (R6 represents an alkyl group).

)、アシル置換イミノ基(R7はアルキル基を表わす。), an acyl-substituted imino group (R7 represents an alkyl group).

)およびフエニレン基]〔?〕−から選択されるOまた
は1以上の基が任意の順序に結合した2価基を表わす。
)で表わされる。)で表わされるアルギニンアミドまた
はその酸付加塩に下記一般式()(上記一般式()中で
R5は1−ナフチル基;2−ナフチル基;ノ叩ゲン原子
、ニトロ基、アルコキシカルボニルオキシ基、ジアルキ
ルアミノ基、シアノ基もしくはアルキル基で置換された
1−ナフチル基または2−ナフチル基を表わし、Xはハ
ロゲン原子を表わす。
) and phenylene group] [? ] - represents a divalent group in which O selected from - or one or more groups are bonded in any order.
). ) to arginine amide or its acid addition salt represented by the following general formula () (in the above general formula (), R5 is a 1-naphthyl group; a 2-naphthyl group; an atom atom, a nitro group, an alkoxycarbonyloxy group, It represents a 1-naphthyl group or a 2-naphthyl group substituted with a dialkylamino group, a cyano group, or an alkyl group, and X represents a halogen atom.

ただし、5−(ジメチルアミノ)−1−ナフチル基を除
く。)で表わされるナフタレンスルホニルハロゲニドま
たは置換ナフタレンスルホニルハロゲニドを反応させて
下記一般式()(上記一般式()中でRは上記一般式(
1)におけると同じ意義を有し、R′は上記一般式()
におけると同じ意義を有する。
However, 5-(dimethylamino)-1-naphthyl group is excluded. ) or a substituted naphthalenesulfonyl halide represented by the following general formula () (in the above general formula (), R is the above general formula ()).
It has the same meaning as in 1), and R' is the above general formula ()
has the same meaning as in .

)で表わされるN2−ナフタレンスルホニルアルギニン
アミド類を得ることによつて達成される。本発明を詳細
に説明すると、本発明で原料として用いられるアルギニ
ンアミドは上記一般式()で表わされるが、上記一般式
中のRを例示すれば次の通りである。
) is achieved by obtaining N2-naphthalenesulfonylarginine amides. To explain the present invention in detail, the argininamide used as a raw material in the present invention is represented by the above general formula (), and examples of R in the above general formula are as follows.

R,およびR2は水素原子、通常炭素数10以下のアル
キル基、通常炭素数15以下のシクロアルキルアルキル
基、または通常炭素数10以下のアルコキシ基もしくは
通常炭素数10以下のアルコキシカルボニル基で置換さ
れた通常炭素数10以下のアルキル基を表わす。
R and R2 are substituted with a hydrogen atom, an alkyl group usually having 10 or less carbon atoms, a cycloalkylalkyl group usually having 15 or less carbon atoms, an alkoxy group usually having 10 or less carbon atoms, or an alkoxycarbonyl group usually having 10 or less carbon atoms. It usually represents an alkyl group having 10 or less carbon atoms.

さらに具体的にはメチル基、エチル基、nプロピル基、
イソプロピル基、n−ブチル基、イソブチル基、n−ペ
ンチル基、n−ヘキシル基、n−ヘプチル基などのアル
キル基、シクロヘキシルメチル基、3−シクロヘキシル
プロピル基などのシクロアルキルアルキル基、またはメ
トキシエチル基、メトキシプロピル基、エトキシエチル
基、エトキシカルボニルメチル基、2−エトキシカルボ
ニルエチル基、3−エトキシカルボニルプロピル基など
のアルコキシ基もしくはアルコキシカルボニル基で置換
されたアルキル基等を挙げることができる。
More specifically, methyl group, ethyl group, n-propyl group,
Alkyl groups such as isopropyl group, n-butyl group, isobutyl group, n-pentyl group, n-hexyl group, n-heptyl group, cycloalkylalkyl group such as cyclohexylmethyl group, 3-cyclohexylpropyl group, or methoxyethyl group , a methoxypropyl group, an ethoxyethyl group, an ethoxycarbonylmethyl group, a 2-ethoxycarbonylethyl group, a 3-ethoxycarbonylpropyl group, or an alkyl group substituted with an alkoxy group or an alkoxycarbonyl group.

zはメチレン基−CH2− およびモノ置換メチレン基
C−(R3は通常炭素数10以下の アルキル基、アシル基、アルコキシ基またはアルコキシ
カルボニル基を表わす。
z represents a methylene group -CH2- or a monosubstituted methylene group C- (R3 usually represents an alkyl group, acyl group, alkoxy group or alkoxycarbonyl group having 10 or less carbon atoms);

)から選択される2以上の基、ならびにオキシ基−0−
、チオ基−S−、通常炭素数10以下のシクロアルキレ
ン基、アルキル置換イミノ基 ( (R6 は通常炭素数10以下のアルキル基を表わす。
), and an oxy group -0-
, thio group -S-, cycloalkylene group usually having 10 or less carbon atoms, alkyl-substituted imino group ((R6 usually represents an alkyl group having 10 or less carbon atoms).

)、アシル置換イミ2ノ基(R7は通常炭 素数10以下のアルキル基を表わす。), acyl-substituted imino group (R7 is usually carbon Represents an alkyl group with a prime number of 10 or less.

)およびフエニレン基{:〕卜から選択されるOまたは
1以上の基が任意の順序に結合した2価基を表わし、上
記の結合する基の数ば通常20以下である。さらに具体
的には上記Rは1−アジリジニル基、1−アゼチジニル
基、3−メトキシ−1アゼチジニル基、3−エトキシ−
1−アゼチジニル基、1−ピロリジニル基、1−ピペリ
ジノ基、4−メチル−1−ピペリジノ基、4−エチル−
1−ピペリジノ基、4−(n−プロピル)一1−ピペリ
ジノ基、4−イソプロピル−1ピペリジノ基、2−メチ
ル−1−ピペリジノ基、3−メチル−1−ピペリジノ基
、2−エトキシカルボニル−1−ピロリジニル基、4−
メトキシ−1−ピペリジノ基、4−アセチル−1−ピペ
リジノ基、4−メトキシカルボニル−1−ピペリジノ基
、1−ヘキサメチレンイミニル基、1−オクタメチレン
イミニル基などの1−ポリメチレンイミニル基またはそ
の誘導体、3−オキサゾリジニル基、3−チアゾリジニ
ル基などのオキサゾール、チアゾール系の基、2−イソ
オキサゾリジニル基、2−イソチアゾリジニル基などの
イソオキサゾール、イソチアゾール系の基、4−モルフ
オリノ基、2・6−ジメチル4−モルフオリノ基、3−
(テトラヒトロー1・3−オキサジニル)基などのオキ
サジン系の基、4−(テトラヒトロー1・4−チアジル
)基などのチアジン系の基、4−メチル−1−ピペラジ
ニル基、4−アセチル−1−ピペラジニル基、2−イソ
インドリニル基、1−インドリニル基、1・2・3・4
−テトラヒトロー2−イソキノリル基、3−アザピング
ロー〔3・2・2〕ノン−3−イル基、1・2・3・4
−テトラヒトロー1−キノリル基等である。本発明方法
によつて得られるN2−ナフタレンスルホニルアルギニ
ンアミド類は上記一般式()によつて表わされる。
) and phenylene group {:] represents a divalent group in which O or one or more groups are bonded in any order, and the number of bonded groups is usually 20 or less. More specifically, the above R is a 1-aziridinyl group, a 1-azetidinyl group, a 3-methoxy-1 azetidinyl group, a 3-ethoxy-
1-azetidinyl group, 1-pyrrolidinyl group, 1-piperidino group, 4-methyl-1-piperidino group, 4-ethyl-
1-piperidino group, 4-(n-propyl)-1-piperidino group, 4-isopropyl-1-piperidino group, 2-methyl-1-piperidino group, 3-methyl-1-piperidino group, 2-ethoxycarbonyl-1 -pyrrolidinyl group, 4-
1-Polymethyleneiminyl groups such as methoxy-1-piperidino group, 4-acetyl-1-piperidino group, 4-methoxycarbonyl-1-piperidino group, 1-hexamethyleneiminyl group, and 1-octamethyleneiminyl group or derivatives thereof, oxazole and thiazole groups such as 3-oxazolidinyl group and 3-thiazolidinyl group, isoxazole and isothiazole groups such as 2-isoxazolidinyl group and 2-isothiazolidinyl group, 4 -morpholino group, 2,6-dimethyl4-morpholino group, 3-
Oxazine groups such as (tetrahydro-1,3-oxazinyl) group, thiazine groups such as 4-(tetrahydro-1,4-thiazyl) group, 4-methyl-1-piperazinyl group, 4-acetyl-1-piperazinyl group. group, 2-isoindolinyl group, 1-indolinyl group, 1, 2, 3, 4
-tetrahydro 2-isoquinolyl group, 3-azapine guro [3.2.2] non-3-yl group, 1.2.3.4
-tetrahydro-1-quinolyl group, etc. The N2-naphthalenesulfonylarginine amide obtained by the method of the present invention is represented by the above general formula ().

アルギニンアミドまたはN2−ナフタレンスルホニルア
ルギニンアミド類の酸付加塩としては塩酸塩、臭化水素
塩、P−トルエンスルホン酸塩、ギ酸塩、酢酸塩などの
無機酸塩、有機酸塩を挙げることができる。
Examples of acid addition salts of argininamide or N2-naphthalenesulfonylargininamides include inorganic acid salts and organic acid salts such as hydrochloride, hydrobromide, P-toluenesulfonate, formate, and acetate. .

本発明で原料として用いられるN2−アルギニンアミド
またはその酸付加塩はアルギニンのグアニジノ基および
α−アミノ基をニトロ化、アセチル化、ホルミル化、プ
タロール化、トリフルオロアセチル化、P−メトキシベ
ンジルオキシカルボニル化、ベンゾイル化、ベンジルオ
キシカルボニル化あるいはトリチル化等によつて保護し
て、これを上記一般式(1)のRに対応するRHで表わ
されるアミンと酸塩化物法、酸アジド法、混合酸無水物
法、活性エステル化法、カルボジイミド法等、常法に従
つて縮合させた後保護基を脱離させることによつて得ら
れる。
N2-argininamide or its acid addition salt used as a raw material in the present invention is a guanidino group and an α-amino group of arginine that are nitrated, acetylated, formylated, putarolated, trifluoroacetylated, and P-methoxybenzyloxycarbonyl. oxidation, benzoylation, benzyloxycarbonylation, tritylation, etc., and then combine it with an amine represented by RH corresponding to R in the above general formula (1) and an acid chloride method, an acid azide method, or a mixed acid method. It can be obtained by condensation according to a conventional method such as an anhydride method, active esterification method, carbodiimide method, etc. and then removing the protective group.

N2−ナフタレンスルホニルアルギニンアミド類または
その酸付加塩のもう一つの原料であるナフタレンスルホ
ニルハロゲニドまたは置換ナフタレンスルホニルハロゲ
ニドは上記一般式()で表わされるが一般式()中でR
′は1−ナフチル基;2−ナフチル基;ハロゲン原子、
ニトロ基、アルコキシカルボニルオキシ基、ジアルキル
アミノ基、シアノ基もしくはアルキル基で置換された1
−ナフチル基または2−ナフチル基を表わす。
Naphthalenesulfonyl halide or substituted naphthalenesulfonyl halide, which is another raw material for N2-naphthalenesulfonylargininamides or acid addition salts thereof, is represented by the above general formula (), and in the general formula (), R
' is 1-naphthyl group; 2-naphthyl group; halogen atom,
1 substituted with a nitro group, alkoxycarbonyloxy group, dialkylamino group, cyano group or alkyl group
-Represents a naphthyl group or a 2-naphthyl group.

具体的には、ナフタレン環の置換基はCl,.Br等の
ハロゲン原子;ニトロ基;メトキシカルボニルオキシ基
、エトキシカルボニルオキシ基等の通常炭素数5以下の
低級アルコキシカルボニルオキシ基;ジメチルアミノ基
、ジエチルアミノ基等の通常炭素数10以下のジアルキ
ルアミノ基;シアノ基;メチル基、エチル基、n−プロ
ピル基、イソプロピル基、n−ブチル基、イソブチル基
、t−ブチル基等の通常炭素数10以下、好ましくは炭
素数5以下のアルキル基等である。なお、5(ジメチル
アミノ)−1−ナフチル基は除く。またXはCl.Br
等の・・ロゲン原子を表わすが、通常ナフタレンスルホ
ニルハロゲニドまたは置換ナフタレンスルホニルハロゲ
ニドとしては、ナフタレンスルホニルクロリドまたは置
換ナフタレンスルホニルクロリドが用いられる。アルギ
ニンアミドまたはその酸付加塩とナフタレンスルホニル
ハロゲニドまたは置換ナフタレンスルホニルハロゲニド
の反応は通常塩基の存在下行われる。
Specifically, the substituents on the naphthalene ring are Cl, . Halogen atoms such as Br; nitro groups; lower alkoxycarbonyloxy groups, usually having 5 or less carbon atoms, such as methoxycarbonyloxy and ethoxycarbonyloxy groups; dialkylamino groups, usually having 10 or less carbon atoms, such as dimethylamino and diethylamino groups; Cyano group; an alkyl group usually having 10 or less carbon atoms, preferably 5 or less carbon atoms, such as a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, or t-butyl group. Note that 5(dimethylamino)-1-naphthyl group is excluded. Also, X is Cl. Br
etc., but as the naphthalenesulfonyl halide or substituted naphthalenesulfonyl halide, naphthalenesulfonyl chloride or substituted naphthalenesulfonyl chloride is usually used. The reaction between argininamide or its acid addition salt and naphthalenesulfonyl halide or substituted naphthalenesulfonyl halide is usually carried out in the presence of a base.

塩基は反応で生成するハロゲン化水素を捕捉し反応を促
進する。塩基としては、トリエチルアミン、ピリジン等
の有機塩基、水酸化ナトリウム、水酸化カリウム、炭酸
カリウム等の一般的な無機塩基を挙げることができる。
The base captures the hydrogen halide produced in the reaction and accelerates the reaction. Examples of the base include organic bases such as triethylamine and pyridine, and common inorganic bases such as sodium hydroxide, potassium hydroxide, and potassium carbonate.

無機塩基は通常水溶液として用いられる。塩基はアルギ
ニンアミドに対し通常当量以上使用される。
Inorganic bases are usually used as aqueous solutions. The base is usually used in an amount equivalent to or more than the amount of argininamide.

原料としてアルギニンアミドの酸付加塩を使用する場合
、アルギニンアミドの酸付加塩をアルギニンアミドに変
えるに十分な量の塩基を過剰に用いることが好ましい。
ナフタレンスルホニルハロゲニドまたは置換ナフタレン
スルホニルハロゲニドは通常等モルのアルギニンアミド
またはその酸付加塩と反応させる。
When using an acid addition salt of argininamide as a raw material, it is preferable to use an excess amount of base sufficient to convert the acid addition salt of argininamide into argininamide.
The naphthalenesulfonyl halide or substituted naphthalenesulfonyl halide is usually reacted with equimolar amounts of arginine amide or its acid addition salt.

アルギニンアミドまたはその酸付加塩とナフタレンスル
ホニルハロゲニドまたは置換ナフタレンスルホニルハロ
ゲニドの反応は一般には溶媒中で行われる。溶媒として
は水:塩化メチレン、クロロホルム、四塩化炭素などの
塩素系溶媒;ベンゼン、トルエン、キシレンなどの芳香
族炭化水素;エーテル、テトラヒドロフラン、ジオキサ
ン、テトラヒドロピランなどのエーテル系溶媒、アセト
ン、メチルエチルケトン、シクロヘキサノンなどのケト
ン系溶媒、ジメチルアセトアミド、ジメチルホルムアミ
ド、テトラメチル尿素、N−メチルピロリドン、ピリジ
ン、キノリンなどの塩基性溶媒または2以上のこれら溶
媒の混合物が用いられる。塩基性溶媒を用いると、これ
ら溶媒は酸受溶剤として作用するので、塩基を添加する
必要はない。
The reaction between argininamide or its acid addition salt and naphthalenesulfonyl halide or substituted naphthalenesulfonyl halide is generally carried out in a solvent. Water as a solvent: Chlorinated solvents such as methylene chloride, chloroform, and carbon tetrachloride; Aromatic hydrocarbons such as benzene, toluene, and xylene; Ether solvents such as ether, tetrahydrofuran, dioxane, and tetrahydropyran, acetone, methyl ethyl ketone, and cyclohexanone. A basic solvent such as ketone solvents such as dimethylacetamide, dimethylformamide, tetramethylurea, N-methylpyrrolidone, pyridine, or quinoline, or a mixture of two or more of these solvents are used. When basic solvents are used, there is no need to add a base since these solvents act as acid acceptors.

反応温度は使用するアルギニンアミドおよび塩基によつ
て異なるが、一般にはO℃から溶媒の沸点までの温度か
ら選ばれる。反応時間は使用するアルギニンアミドによ
つて異なるが、通常10分から15時間の範囲から選ば
れる。
The reaction temperature varies depending on the arginine amide and base used, but is generally selected from a temperature range of 0° C. to the boiling point of the solvent. The reaction time varies depending on the arginine amide used, but is usually selected from a range of 10 minutes to 15 hours.

反応終了後生成した塩類を水洗して除去し、溶媒を留去
後、水および/または溶媒で生成物を洗浄するとN2−
ナフタレンスルホニルアルギニンアミド類が得られる。
After the reaction is completed, the salts produced are removed by washing with water, and the solvent is distilled off. When the product is washed with water and/or solvent, N2-
Naphthalenesulfonylarginine amides are obtained.

またこうして得られたN2ナフタレンスルホニルアルギ
ニンアミド類にエーテルおよび酸(たとえば塩酸、P−
トルエンスルホン酸など)を加え、生成したN2−ナフ
タレンスルホニルアルギニンアミド類の酸付加塩を単離
することもできる。次に本発明の方法によつて得られる
N2−ナフタレンスルホニルアルギニンアミド類の薬理
効果を説明する。
Also, the N2 naphthalenesulfonylarginine amide obtained in this way is combined with an ether and an acid (e.g. hydrochloric acid, P-
Toluenesulfonic acid, etc.) can also be added, and the generated acid addition salt of N2-naphthalenesulfonylargininamide can be isolated. Next, the pharmacological effects of N2-naphthalenesulfonylargininamides obtained by the method of the present invention will be explained.

既述の通りN2−ナフタレンスルホニルアルギニンアミ
ド類は抗トロンビン作用を有するが、既知の抗トロンビ
ン剤であるTAME(N2−(Pトリルスルホニル)−
L−アルギニン、メチルエステノ(ハ)とN2−ナフタ
レンスルホニルアルギニンアミド類の抗トロンビン作用
をフイブリノーゲン凝固時間を測定して比較した。
As mentioned above, N2-naphthalenesulfonylarginine amides have antithrombin effects, but TAME (N2-(P-tolylsulfonyl)-
The antithrombin effects of L-arginine, methylesterno(c), and N2-naphthalenesulfonylargininamides were compared by measuring fibrinogen clotting time.

試1験は次のようにして行つた。牛フイブリノーゲン(
コーン フラクシヨン1(COllnFractiOn
l)、アーマ一(ArmOur)社製)150即を40
m1のボレート サラインバツJャA(BOrateSa
llneBuffer(PH7.4))に溶解した溶液
0,8m1と0.1m1のボレート サライン バツフ
ア(対照試料)または試料溶液を氷冷下で混和し、さら
に5units/mlのトロンビン(持田製薬(株)製
試薬)0.1m1を氷冷下で添加してよく混和し直ちに
25℃の恒温槽に移す。
Test 1 was conducted as follows. Bovine fibrinogen (
COllnFractiOn
l), manufactured by Armour) 150 40
m1 borate Sarainbatuja A (BOrateSa
0.8 ml of the solution dissolved in llneBuffer (PH7.4) and 0.1 ml of borate saline buffer (control sample) or sample solution were mixed under ice cooling, and then 5 units/ml of thrombin (manufactured by Mochida Pharmaceutical Co., Ltd.) was mixed. Add 0.1 ml of reagent under ice-cooling, mix well, and immediately transfer to a constant temperature bath at 25°C.

恒温槽に入れた瞬間にストツプウオツチを始動させ、フ
イプリン系を認めた時までの時間を測定した。試料無添
加の場合(対照実験)の凝固時間は5055秒であつた
。実験結果を表−1に示す。
A stopwatch was started the moment the sample was placed in the thermostatic chamber, and the time until filipin formation was observed was measured. The coagulation time when no sample was added (control experiment) was 5055 seconds. The experimental results are shown in Table-1.

表−1で凝固時間を2倍に延長する濃度とは、対照実験
での凝固時間50−55秒を凝固時間100−110秒
に延長するのに必要な濃度を表わす。TAMEについて
は、その凝固時間を2倍に延長する濃度は1100μM
であつた。
In Table 1, the concentration that doubles the clotting time refers to the concentration required to prolong the clotting time from 50-55 seconds in the control experiment to 100-110 seconds. For TAME, the concentration that doubles its clotting time is 1100 μM.
It was hot.

なお、下記表−1においてN2−ナフタレンスルホニル
アルギニンアミド類は、表中のRsR′および付加物を
特定することによつて表わす。
In Table 1 below, N2-naphthalenesulfonylarginine amides are indicated by specifying RsR' and adducts in the table.

次に本発明を実施例にて具体的に説明するが、その要旨
を超えない限り本発明はこれら実施例に限定されない。
実施例 1 4−メチル−1−(L−アルギニル)ピペリジン1.0
7(0.0039モル)を炭酸カリウム0.65y(0
.0047モル)およびH2OlOmlからなる溶液に
懸濁させ、0℃に冷却する。
Next, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these Examples unless the gist thereof is exceeded.
Example 1 4-methyl-1-(L-arginyl)piperidine 1.0
7 (0.0039 mol) to potassium carbonate 0.65y (0
.. 0047 mol) and H2OlOml and cooled to 0°C.

この懸濁液に激しく攪拌しながら、1−ナフタレンスル
ホニルクロリド1.17(0.0047モル)を100
m1のジオキサンに溶解した溶液を30分かけて滴下す
る。室温で5時間攪拌後、析出物をr去し、溶媒を減圧
留去する。10%酢酸含有クロロホルムを加え、不溶物
を▲去後溶媒を留去すると、粉体状の4−メチル−1−
(N2−(1ナフタレンスルホニル)−L−アルギニル
)ピペリジン・酢酸塩を得る。
While vigorously stirring, 1.17 (0.0047 mol) of 1-naphthalenesulfonyl chloride was added to this suspension at 100%.
ml of a solution in dioxane is added dropwise over 30 minutes. After stirring at room temperature for 5 hours, the precipitate was removed and the solvent was distilled off under reduced pressure. Add 10% acetic acid-containing chloroform, remove insoluble matter, and then distill off the solvent to obtain powdered 4-methyl-1-
(N2-(1 naphthalenesulfonyl)-L-arginyl)piperidine acetate is obtained.

メタノール−エーテルより再沈澱して精製する。収率6
1%元素分析;C22H3,O3N5S−CH3COO
Hとして実施例 24−(L−アルギニル)モルホリン
1.0y(0.0041モル)にクロロホルム100m
1およびトリエチルアミン0.52f(0.0052モ
ル)を加える。
It is purified by reprecipitation from methanol-ether. Yield 6
1% elemental analysis; C22H3,O3N5S-CH3COO
Example 2 1.0y (0.0041 mol) of 4-(L-arginyl)morpholine and 100ml of chloroform as H
1 and 0.52 f (0.0052 mol) of triethylamine are added.

Claims (1)

【特許請求の範囲】 1 下記一般式( I ) ▲数式、化学式、表等があります▼( I )(上記一般
式( I )中でRは一般式(1)▲数式、化学式、表等
があります▼(式中でR_1およびR_2は水素原子、
アルキル基、シクロアルキルアルキル基またはアルコキ
シ基もしくはアルコキシカルボニル基で置換されたアル
キル基を表わす。 )または一般式(2)−NZ(式中でZはメチレン基−
CH_2−およびモノ置換メチレン基▲数式、化学式、
表等があります▼(R_3はアルキル基、アシル基、ア
ルコキシ基またはアルコキシカルボニル基を表わす。)
から選択される2以上の基ならびにオキシ基−O−、チ
オ基−S−、シクロアルキレン基、アルキル置換イミノ
基▲数式、化学式、表等があります▼(R_6はアルキ
ル基を表わす。)、アシル置換イミノ基▲数式、化学式
、表等があります▼(R_7はアルキル基を表わす。 )およびフェニレン基▲数式、化学式、表等があります
▼から選択される0または1以上の基が任意の順序に結
合した2価基を表わす。)で表わされる。)で表わされ
るアルギニンアミドまたはその酸付加塩と下記一般式(
II)R′−SO_2X(II) (上記一般式(II)中でR′は1−ナフチル基;2−ナ
フチル基;ハロゲン原子、ニトロ基、アルコキシカルボ
ニルオキシ基、ジアルキルアミノ基、シアノ基もしくは
アルキル基で置換された1−ナフチル基または2−ナフ
チル基を表わし、Xはハロゲン原子を表わす。 ただしR′は5−(ジメチルアミノ)−1−ナフチル基
を除く。)で表わされるナフタレンスルホニルハロゲニ
ドまたは置換ナフタレンスルホニルハロゲニドを反応さ
せることを特徴とする下記一般式(III)▲数式、化学
式、表等があります▼(III)(上記一般式(III)中で
Rは上記一般式( I )におけると同じ意義を有し、R
′は上記一般式(II)におけると同じ意義を有する。 )で表わされるN^2−ナフタレンスルホニルアルギニ
ンアミド類またはその酸付加塩の製造方法。
[Claims] 1 The following general formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the above general formula (I), R is the general formula (1)▲The mathematical formulas, chemical formulas, tables, etc. ▼(In the formula, R_1 and R_2 are hydrogen atoms,
It represents an alkyl group, a cycloalkylalkyl group, or an alkyl group substituted with an alkoxy group or an alkoxycarbonyl group. ) or general formula (2) -NZ (in the formula, Z is a methylene group -
CH_2- and mono-substituted methylene group ▲ mathematical formula, chemical formula,
There are tables, etc. ▼ (R_3 represents an alkyl group, acyl group, alkoxy group, or alkoxycarbonyl group.)
Two or more groups selected from oxy group -O-, thio group -S-, cycloalkylene group, alkyl-substituted imino group ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (R_6 represents an alkyl group), acyl Substituted imino group ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ (R_7 represents an alkyl group) and phenylene group ▲ Numerical formulas, chemical formulas, tables, etc. are available ▼ Zero or more groups selected from the following in any order Represents a bonded divalent group. ). ) or its acid addition salt represented by the following general formula (
II) R'-SO_2X(II) (In the above general formula (II), R' is a 1-naphthyl group; a 2-naphthyl group; a halogen atom, a nitro group, an alkoxycarbonyloxy group, a dialkylamino group, a cyano group, or an alkyl group) represents a 1-naphthyl group or 2-naphthyl group substituted with a group, and X represents a halogen atom. However, R' excludes a 5-(dimethylamino)-1-naphthyl group. or the following general formula (III) characterized by reacting substituted naphthalenesulfonyl halide ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (III) (In the above general formula (III), R is the above general formula (I) has the same meaning as in R
' has the same meaning as in the above general formula (II). ) or an acid addition salt thereof.
JP50023635A 1974-11-08 1975-02-26 Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof Expired JPS5939423B2 (en)

Priority Applications (50)

Application Number Priority Date Filing Date Title
JP50023635A JPS5939423B2 (en) 1975-02-26 1975-02-26 Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof
NL7512637A NL7512637A (en) 1974-11-08 1975-10-29 PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT, THE MEDICINAL PRODUCT CONTAINED THEREFORE AND PROCESS FOR THE PREPARATION OF THE ACTIVE COMPONENT.
GB45339/75A GB1516668A (en) 1974-11-08 1975-10-31 N2-naphthalenesulphonyl-l-arginine esters and amides
CA239,255A CA1073914A (en) 1974-11-08 1975-11-05 N2-naphthalene sulfonyl-l-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof and processes for preparing the same
DK498975A DK498975A (en) 1974-11-08 1975-11-06 N2-NAPHTHALENES SULPHONYL-L-ARGININE DERIVATIVES AND PHARMACEUTICAL ACCEPTABLE ACID ADDITIONAL SALTS THEREOF AND THEIR USE AND PROCEDURE
SE7512530A SE431204B (en) 1974-11-08 1975-11-07 PROCEDURE FOR THE PREPARATION OF N? 722-Naphthalenesulfonyl-L-Arginine and Amides or Pharmaceutically Acceptable Acid Addition Salts thereof
FR7534105A FR2290193A1 (en) 1974-11-08 1975-11-07 N2-NAPHTALENESULFONYL-L-ARGININE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NO753733A NO753733L (en) 1974-11-08 1975-11-07
DE19752550088 DE2550088A1 (en) 1974-11-08 1975-11-07 N HIGH 2 -NAPHTALINE SULFONYL-L-ARGININESTER AND -AMIDE
US05/638,985 US4055636A (en) 1974-11-08 1975-12-09 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/653,217 US4055651A (en) 1974-11-08 1976-01-28 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/656,014 US4041156A (en) 1974-11-08 1976-02-06 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/656,870 US4046876A (en) 1974-11-08 1976-02-10 N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/669,743 US4070457A (en) 1974-11-08 1976-03-24 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/671,435 US4062963A (en) 1974-11-08 1976-03-29 N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/671,568 US4049645A (en) 1974-11-08 1976-03-29 N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/671,436 US4066758A (en) 1974-11-08 1976-03-29 N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/703,704 US4069323A (en) 1974-11-08 1976-07-08 N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US05/713,486 US4073914A (en) 1974-11-08 1976-08-11 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/723,474 US4096255A (en) 1974-11-08 1976-09-14 N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US05/728,051 US4104392A (en) 1974-11-08 1976-09-30 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US05/760,668 US4073913A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,745 US4066773A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,929 US4101653A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-argininamides and the pharmaceutically acceptable salts thereof
US05/760,587 US4072757A (en) 1974-11-08 1977-01-19 N2 alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,677 US4069317A (en) 1974-11-08 1977-01-19 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,586 US4066759A (en) 1974-11-08 1977-01-19 N2 -naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/760,740 US4069329A (en) 1974-11-08 1977-01-19 N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/760,738 US4073892A (en) 1974-11-08 1977-01-19 N2 -alkoxynaphthylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,667 US4073891A (en) 1974-11-08 1977-01-19 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,744 US4072743A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,654 US4108986A (en) 1974-11-08 1977-01-19 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,719 US4073916A (en) 1974-11-08 1977-01-19 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,673 US4125619A (en) 1974-11-08 1977-01-19 N2 -naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US05/760,585 US4072744A (en) 1974-11-08 1977-01-19 N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,727 US4069318A (en) 1974-11-08 1977-01-19 N2 -Alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,672 US4093712A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/760,676 US4097472A (en) 1974-11-08 1977-01-19 N2 -arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
US05/776,195 US4097591A (en) 1974-11-08 1977-03-10 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/804,334 US4125604A (en) 1974-11-08 1977-06-07 N2-Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/804,331 US4140681A (en) 1974-11-08 1977-06-07 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/804,368 US4131673A (en) 1974-11-08 1977-06-07 N2 -arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/819,872 US4133880A (en) 1974-11-08 1977-07-28 N2 -Substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US05/829,483 US4139529A (en) 1974-11-08 1977-08-31 N2 -Naphthalenesulfonyl-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
US05/844,196 US4154828A (en) 1974-11-08 1977-10-21 N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/844,188 US4117127A (en) 1974-11-08 1977-10-21 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/844,181 US4168307A (en) 1974-11-08 1977-10-21 N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US05/902,855 US4173630A (en) 1974-11-08 1978-05-04 N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US05/938,711 US4201863A (en) 1974-11-08 1978-08-31 N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
UA2814248A UA8371A1 (en) 1974-11-08 1979-08-30 Process for the preparation of n2-arylsulfonyl-l-argininamides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP50023635A JPS5939423B2 (en) 1975-02-26 1975-02-26 Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof

Publications (2)

Publication Number Publication Date
JPS51125263A JPS51125263A (en) 1976-11-01
JPS5939423B2 true JPS5939423B2 (en) 1984-09-22

Family

ID=12116026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50023635A Expired JPS5939423B2 (en) 1974-11-08 1975-02-26 Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof

Country Status (1)

Country Link
JP (1) JPS5939423B2 (en)

Also Published As

Publication number Publication date
JPS51125263A (en) 1976-11-01

Similar Documents

Publication Publication Date Title
US4018913A (en) N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4055636A (en) N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4046876A (en) N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4104392A (en) N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
CN103936763A (en) Oxazolidinone compound as well as preparing method and purpose thereof
BRPI0414382B1 (en) 4- (4-AMINOPHENYL) -3-MORPHOLINONE PREPARATION PROCESS
CN113912560B (en) Oxazole histone deacetylase inhibitor and preparation method and application thereof
Rinaldi et al. Use of liquid crystal induced circular dichroism for absolute configurational assignments of. beta.-amino alcohols
US2868833A (en) Aliphatic diamines and salts thereof
JPS5939423B2 (en) Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof
SI9210142A (en) 3-substituted 1,2,3,4-oxitriazole-5-imin compounds, procedure for their preparation and preparations comprising them
JP6906105B2 (en) Compounds that inhibit ROCK and their use
JPS5913501B2 (en) Method for producing N↑2-naphthalenesulfonylargininamides or acid addition salts thereof
JPS5913503B2 (en) Method for producing N↑2-naphthalenesulfonylarginine esters or amides or acid addition salts thereof
US4073891A (en) N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5939424B2 (en) Method for producing N↓2-naphthalenesulfonylargininamides or acid addition salts thereof
JPS5913500B2 (en) Method for producing N↑2-naphthalenesulfonylargininamides or acid addition salts thereof
JPS6017782B2 (en) N↑2-arylsulfonyl-L-argininamides and pharmaceutically acceptable salts thereof
JPS5940146B2 (en) Method for producing N↑2-naphthalenesulfonylargininamides or acid addition salts thereof
JPS5913504B2 (en) NG-substituted-N↑2-(5,6,7,8-tetrahydro-1 or 2-naphthalenesulfonyl)argininamide or its acid addition salt
JPS5912663B2 (en) Method for producing N↑g-substituted-N↑2-naphthalenesulfonylargininamides or acid addition salts thereof
Entenmann et al. INVESTIGATION OF THE THIAZOLE SERIES 7. SYNTHESIS, STRUCTURE AND PROPERTIES OF 2-HYDROXIMINO-1, 3-THIAZOLIDINE-4-ONES
JPS5941991B2 (en) Method for producing N↑2-substituted arginine amides or acid addition salts thereof
KR101124879B1 (en) Novel heteroaryl carboxamides